Serlopitant
- Generic Name
- Serlopitant
- Drug Type
- Small Molecule
- Chemical Formula
- C29H28F7NO2
- CAS Number
- 860642-69-9
- Unique Ingredient Identifier
- 277V92K32B
- Background
Serlopitant has been investigated for the treatment of Prurigo Nodularis.
A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)
- First Posted Date
- 2014-07-22
- Last Posted Date
- 2021-05-20
- Lead Sponsor
- Vyne Therapeutics Inc.
- Target Recruit Count
- 128
- Registration Number
- NCT02196324
- Locations
- 🇩🇪
Study Site 07, Berlin-Mitte, Germany
🇩🇪Study Site 08, Bonn, Germany
🇩🇪Study Site 12, Dusseldorf, Germany
VPD-737 for Treatment of Chronic Pruritus
- First Posted Date
- 2013-09-26
- Last Posted Date
- 2022-05-13
- Lead Sponsor
- Vyne Therapeutics Inc.
- Target Recruit Count
- 257
- Registration Number
- NCT01951274
- Locations
- 🇺🇸
Stanford University, Medical Dermatology, Redwood City, California, United States
🇺🇸Dermatology of Boca, Boca Raton, Florida, United States
🇺🇸Skin Care Research, Boca Raton, Florida, United States
Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)
Phase 2
Completed
- Conditions
- Urinary IncontinenceOveractive Bladder
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2021-05-19
- Lead Sponsor
- Vyne Therapeutics Inc.
- Target Recruit Count
- 557
- Registration Number
- NCT00290563
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath